» Articles » PMID: 32251625

Do Chronic Respiratory Diseases or Their Treatment Affect the Risk of SARS-CoV-2 Infection?

Overview
Publisher Elsevier
Specialty Pulmonary Medicine
Date 2020 Apr 7
PMID 32251625
Citations 227
Authors
Affiliations
Soon will be listed here.
Citing Articles

Using Quantitative Bias Analysis to Adjust for Misclassification of COVID-19 Outcomes: An Applied Example of Inhaled Corticosteroids and COVID-19 Outcomes.

Bokern M, Rentsch C, Quint J, Hunnicutt J, Douglas I, Schultze A Pharmacoepidemiol Drug Saf. 2025; 34(1):e70086.

PMID: 39776023 PMC: 11706700. DOI: 10.1002/pds.70086.


Risk factors for all-cause mortality during the COVID-19 pandemic compared with the pre-pandemic period in an adult population of Arkhangelsk, Russia.

Krieger E, Kudryavtsev A, Sharashova E, Samodova O, Postoev V Sci Rep. 2025; 15(1):1050.

PMID: 39774287 PMC: 11706959. DOI: 10.1038/s41598-025-85360-0.


The Role of Age and Comorbidity Interactions in COVID-19 Mortality: Insights from Cardiac and Pulmonary Conditions.

Patrascu R, Dumitru C, Laza R, Besliu R, Gug M, Zara F J Clin Med. 2025; 13(24.

PMID: 39768431 PMC: 11677844. DOI: 10.3390/jcm13247510.


Comparative analysis of COVID-19-related mortality risk in chronic lower respiratory disease and interstitial lung disease.

Hafzalla G, Ji H, Jeganathan N Sarcoidosis Vasc Diffuse Lung Dis. 2024; 41(4):e2024057.

PMID: 39655583 PMC: 11708943. DOI: 10.36141/svdld.v41i4.16139.


Susceptibility to and severity of SARS-CoV-2 infection according to prescription drug use-an observational study of 46,506 Danish healthcare workers.

Eiken A, Bliddal S, Villumsen M, Iversen K, Bundgaard H, Hasselbach R PLoS One. 2024; 19(11):e0311260.

PMID: 39602471 PMC: 11602038. DOI: 10.1371/journal.pone.0311260.


References
1.
Yamaya M, Nishimura H, Deng X, Sugawara M, Watanabe O, Nomura K . Inhibitory effects of glycopyrronium, formoterol, and budesonide on coronavirus HCoV-229E replication and cytokine production by primary cultures of human nasal and tracheal epithelial cells. Respir Investig. 2020; 58(3):155-168. PMC: 7102607. DOI: 10.1016/j.resinv.2019.12.005. View

2.
Stockman L, Bellamy R, Garner P . SARS: systematic review of treatment effects. PLoS Med. 2006; 3(9):e343. PMC: 1564166. DOI: 10.1371/journal.pmed.0030343. View

3.
Su N, Lin J, Chen P, Li J, Wu C, Yin K . Evaluation of asthma control and patient's perception of asthma: findings and analysis of a nationwide questionnaire-based survey in China. J Asthma. 2013; 50(8):861-70. DOI: 10.3109/02770903.2013.808346. View

4.
. Preliminary Estimates of the Prevalence of Selected Underlying Health Conditions Among Patients with Coronavirus Disease 2019 - United States, February 12-March 28, 2020. MMWR Morb Mortal Wkly Rep. 2020; 69(13):382-386. PMC: 7119513. DOI: 10.15585/mmwr.mm6913e2. View

5.
Onder G, Rezza G, Brusaferro S . Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy. JAMA. 2020; 323(18):1775-1776. DOI: 10.1001/jama.2020.4683. View